Your browser doesn't support javascript.
loading
Bone Health in Pediatric Patients With Crohn Disease.
Rozes, Sylvana; Guilmin-Crepon, Sophie; Alison, Marianne; Thomas, Edouard; Hugot, Jean-Pierre; Viala, Jerome; Martinez-Vinson, Christine.
Afiliação
  • Rozes S; Gastroentérologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris.
  • Guilmin-Crepon S; Unité d'Epidémiologie Clinique, Unité de Recherche Clinique, Inserm CIC-EC 1426. Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris.
  • Alison M; Radiologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris.
  • Thomas E; Endocrinology, Bone Diseases and Genetics Unit, Children Hospital, Toulouse University Hospital, Toulouse.
  • Hugot JP; Gastroentérologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris.
  • Viala J; Université Paris Diderot Sorbonne Paris-Cité, INSERM UMR1149, Centre de Recherche sur l'inflammation, Paris, France.
  • Martinez-Vinson C; Gastroentérologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Paris.
J Pediatr Gastroenterol Nutr ; 73(2): 231-235, 2021 08 01.
Article em En | MEDLINE | ID: mdl-33908740
OBJECTIVE: The aim of our study was to examine longitudinal changes in bone mineral density (BMD) of children and adolescents with Crohn disease (CD), and risk factors related to low BMD. PATIENTS AND METHODS: All patients ages from 2 to 18 years with CD who underwent dual-energy X-ray absorptiometry (DXA) at diagnosis and at the end of follow-up between 1999 and 2018 were considered for inclusion in this retrospective study. Factors related to changes in BMD at diagnosis and during follow-up were investigated. RESULTS: One hundred and ninety-three patients had the two DXA required. At diagnosis, 36 patients (18.7%) had a low BMD.At the end of follow-up, 31 patients (16%). One hundred and sixty-four patients did not have the two DXA required.In included CD, BMD values were lower in the lumbar spine (LS) than in total body less head (TBLH), as well at diagnosis (P < 0.0001) or at the end of follow-up (P = 0.001).At diagnosis, only growth impairment or low BMI was associated with low BMD (P < 0.0001), only cumulative dose of corticosteroid at the end of follow-up (P = 0.01). CONCLUSION: The high prevalence of low BMD in children and adolescents with IBD highlights the importance of evaluating BMD in these patients at the time of diagnosis and throughout the course of their treatment. Special attention must be given to patients with height delay or low BMI at diagnosis. Long-term glucocorticoid therapy is the main clinical risk factor associated with low BMD at the end of follow-up.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Ósseas Metabólicas / Doença de Crohn Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Ósseas Metabólicas / Doença de Crohn Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article